NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$1.76
-0.02 (-1.12%)
Open$1.82
Previous Close$1.78
Day High$1.83
Day Low$1.73
52W High$25.40
52W Low$1.10
Volume—
Avg Volume63.0K
Market Cap3.19M
P/E Ratio—
EPS$-10.79
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,901.7% upside
Current
$1.76
$1.76
Target
$35.23
$35.23
$27.84
$35.23 avg
$57.14
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |
| Rev Growth | +15.5% | +19.0% | +13.7% |
| Debt/Equity | 0.19 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |